Drug Manufacturing: Industry Urges FDA “For Cause” Preapproval Inspections
This article was originally published in The Tan Sheet
Executive Summary
FDA should consider moving to "for cause" preapproval inspections (PAIs) as part of its quality systems initiative, drug manufacturers told FDA at the Product Quality Research Institute/FDA conference in Washington, D.C. April 24
You may also be interested in...
FDA GMP Initiative Shifts Warning Letter Review Back To Centers
The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of FDA's initiative to create a risk-based approach to pharmaceutical manufacturing
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands